Wegovy's New 7.2mg Dose: What the Updated Guidance Means for Weight Loss Patients

The world of medical weight management continues to evolve, and one of the most significant recent developments involves Wegovy® (semaglutide).

For many people across the UK, Wegovy has already transformed what is possible when it comes to achieving and maintaining meaningful weight loss. Now, updated guidance has introduced an important new option for eligible patients: a higher maintenance dose of 7.2mg.

This development has generated considerable interest among healthcare professionals and patients alike because it has the potential to deliver even greater weight loss outcomes for some individuals living with obesity.

But what exactly has changed, who might benefit, and what does this mean for people currently taking Wegovy?

Let's take a closer look.

A Quick Refresher: What Is Wegovy?

Wegovy contains semaglutide, a GLP-1 receptor agonist that works by mimicking a naturally occurring hormone involved in appetite regulation.

It helps people lose weight by:

• Reducing hunger
• Increasing feelings of fullness
• Slowing stomach emptying
• Helping reduce calorie intake naturally

Unlike traditional diets that rely heavily on willpower, Wegovy works with the body's appetite-regulating systems, helping many patients feel satisfied with smaller portions and experience fewer cravings.

Wegovy is licensed in the UK for weight management in eligible adults and adolescents aged 12 years and above. It is also the only once-weekly weight management medication that carries an indication for reducing the risk of major adverse cardiovascular events in certain adults with obesity or overweight and established cardiovascular disease.

The Previous Wegovy Dosing Schedule

Until recently, the standard maintenance dose for most patients was 2.4mg once weekly.

Patients would gradually increase their dose over a 16-week period to help minimise gastrointestinal side effects such as nausea, vomiting and diarrhoea. The typical dose escalation schedule involved:

• 0.25mg
• 0.5mg
• 1mg
• 1.7mg
• 2.4mg maintenance dose

For many patients, this dose delivered impressive results.

Clinical studies demonstrated average weight loss of approximately 15-17% when combined with a reduced-calorie diet and increased physical activity.

However, obesity is a complex chronic condition, and not every patient responds in exactly the same way.

This led researchers to investigate whether a higher dose could deliver even greater benefits.

What Has Changed?

The major update is that eligible patients using Wegovy for weight management may now increase their dose beyond 2.4mg to a new maintenance dose of 7.2mg after spending at least four weeks on the 2.4mg dose.

This is not a dose increase that every patient will automatically require.

Instead, it provides healthcare professionals with an additional treatment option for suitable individuals who may benefit from further weight loss support.

Importantly, any dose adjustment should always be guided by a qualified healthcare professional.

What Did the Research Show?

The updated guidance is based on findings from the STEP UP clinical trial.

This large Phase 3b study evaluated the effectiveness of once-weekly Wegovy 7.2mg in adults living with obesity who did not have type 2 diabetes.

The results attracted significant attention within the obesity medicine community.

Over 72 weeks, participants receiving Wegovy 7.2mg achieved approximately 19-21% weight loss, compared with around 4% in the placebo group.

Perhaps even more striking was the number of participants achieving substantial weight loss milestones.

More than nine out of ten patients achieved at least 5% weight loss, while around one in three patients achieved weight loss of 25% or more.

These levels of weight reduction begin to approach outcomes historically associated with some forms of bariatric surgery.

It's Not Just About the Number on the Scales

One of the most interesting findings from the STEP UP programme relates to body composition.

A common concern with weight loss is the potential loss of muscle mass alongside body fat.

The research found that approximately 84.5% of weight lost with Wegovy came from body fat, while muscle function was preserved. Researchers observed improvements in overall body composition, with no clinically meaningful reduction in functional muscle capacity.

This is important because maintaining muscle strength supports long-term health, mobility and physical function.

More Than Weight Loss: Heart Health Benefits

Another reason Wegovy continues to stand out is its cardiovascular indication.

The SELECT trial demonstrated that Wegovy reduced the risk of major adverse cardiovascular events, including cardiovascular death, non-fatal heart attack and non-fatal stroke, by 20% in eligible adults with established cardiovascular disease and obesity or overweight.

Interestingly, analyses suggest that some of these cardiovascular benefits may occur independently of the amount of weight lost, highlighting that Wegovy's effects extend beyond simply helping patients reduce body weight.

Does Everyone Need the 7.2mg Dose?

No.

This is perhaps the most important message for patients.

Many individuals achieve excellent results on the existing 2.4mg maintenance dose.

The introduction of 7.2mg simply provides another option for patients who may benefit from additional treatment intensity under appropriate medical supervision.

Weight management is highly individualised.

Factors such as weight loss progress, treatment response, tolerability and overall health goals all influence prescribing decisions.

What About Side Effects?

As with all GLP-1 medications, gastrointestinal side effects remain the most commonly reported adverse reactions.

These may include:

• Nausea
• Vomiting
• Diarrhoea
• Constipation
• Abdominal discomfort

The updated guidance continues to emphasise gradual dose escalation to help minimise these effects. If significant gastrointestinal symptoms occur, healthcare professionals may recommend delaying dose increases or temporarily returning to a previous dose until symptoms improve.

Patients should always discuss any side effects with their healthcare provider.

What This Means for Patients

The introduction of Wegovy 7.2mg reflects a growing understanding that obesity is a chronic medical condition requiring personalised treatment approaches.

For some patients, the traditional 2.4mg maintenance dose may remain entirely appropriate.

For others, the higher dose may offer an opportunity to achieve greater weight loss and potentially improve obesity-related health outcomes.

What is clear is that treatment options continue to evolve rapidly, providing more choices and more personalised pathways than ever before.

How 24 HR Pharmacy Can Help

At 24 HR Pharmacy, we understand that every weight loss journey is unique.

Our qualified healthcare professionals assess each patient individually to determine the most appropriate treatment pathway based on medical history, eligibility and personal goals.

Whether you're considering Wegovy for the first time, currently using semaglutide treatment, or looking to understand the latest developments in obesity medicine, our team is here to provide trusted guidance and support.

Final Thoughts

The introduction of Wegovy's new 7.2mg maintenance dose represents one of the most important updates in obesity treatment this year.

Clinical trial data suggests that eligible patients may achieve even greater weight loss than previously seen with the standard 2.4mg maintenance dose, while continuing to benefit from Wegovy's established effects on appetite regulation and cardiovascular risk reduction.

As obesity treatment continues to advance, patients now have access to increasingly personalised options that recognise weight management as a long-term health journey rather than a short-term goal.

If you're interested in learning more about Wegovy and whether it may be suitable for you, the healthcare team at 24 HR Pharmacy can help you explore your options safely and responsibly.